2025-07-22 - Analysis Report
Okay, here's a report analyzing Merck & Co Inc (MRK) based on the provided data.

## Merck & Co Inc (MRK) Stock Analysis

Merck & Co Inc is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (MRK):** -5.23%
*   **Cumulative Return (VOO):** 97.07%
*   **Divergence:**
    *   **Current:** -100.8
    *   **Range:** Max 23.1, Min -100.8
    *   **Relative Divergence:** 0.0

**Analysis:**

MRK has significantly underperformed the S&P 500 (VOO) over the analyzed period. The large negative divergence suggests substantial underperformance compared to the benchmark. A relative divergence of 0.0 indicates that the current divergence is at the lowest point in the observed range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
| :---------- | :----- | :----- | :------ | :----- | :------ |
| 2015-2017  | 5.0%   | 58.2% | -24.0%  | -0.0  | 134.8  |
| 2016-2018  | 43.0%  | 66.4% | 25.0%   | -0.1  | 183.1  |
| 2017-2019  | 40.0%  | 66.4% | 11.0%   | 0.3   | 217.9  |
| 2018-2020  | 20.0%  | 66.4% | 0.0%    | 0.3   | 196.0  |
| 2019-2021  | -1.0%  | 65.6% | -50.0%  | 0.3   | 192.4  |
| 2020-2022  | 13.0%  | 69.5% | 11.0%   | 0.3   | 278.6  |
| 2021-2023  | 31.0%  | 69.5% | 13.0%   | 0.3   | 273.8  |
| 2022-2024  | -7.0%  | 69.5% | -33.0%  | 0.2   | 249.8  |
| 2023-2025  | -57.0% | 69.6% | -106.0% | 0.5   | 199.2  |

**Analysis:**

*   **CAGR:** Fluctuates significantly, with recent periods showing negative growth.
*   **MDD:** Remains high, indicating substantial potential drawdowns.
*   **Alpha:** Mostly negative, especially in recent periods, suggesting underperformance relative to its benchmark.
*   **Beta:** Remains low (0.2~0.5), suggesting the stock's volatility is less sensitive to market movements
*   **Cap:** Market capitalization has declined significantly in the most recent period.

### 2. Recent Price Action

*   **Current Price:** 79.31
*   **Previous Close:** 79.96
*   **Change:** -0.81 (-0.81%)
*   **5-day Moving Average:** 80.95
*   **20-day Moving Average:** 81.18
*   **60-day Moving Average:** 79.78

**Analysis:**

The price is currently below both the 5-day and 20-day moving averages, suggesting a short-term downtrend. It's slightly below the 60-day moving average.  The slight decrease from the previous close could be indicative of a small negative reaction in the market.

### 3. Technical Indicators & Expected Return

*   **MRI:** 0.3383 (Low Risk)
*   **RSI:** 50.54
*   **PPO:** -0.39
*   **Hybrid Signal:** cash_70%_Sell 69.9% of holdings (1072 shares - Caution - MRI:0.34)
*   **Delta_Previous_Relative_Divergence:** -3.3 (Negative - short-term decline)
*   **Expected Return:** -1127.7%

**Analysis:**

*   The MRI indicates a low risk level.
*   The RSI is neutral, suggesting neither overbought nor oversold conditions.
*   The PPO being negative suggests a bearish trend.
*   The hybrid signal indicates a cautious stance.  The recommendation is to significantly reduce holdings and increase cash position.
*   The negative delta indicates a recent decline in relative divergence, reinforcing the short-term downtrend.
*   The exceptionally large negative expected return is a major red flag, suggesting a very pessimistic outlook for future performance relative to the S&P 500. Given the significant change in price, the recent market volatility might contribute to some fluctuation.

### 4. Recent News & Events

*   **2025-07-21:** Major business developments, regulatory changes, or market events.
*   **2025-07-20:** Analyst discussions on performance and outlook.
*   **2025-07-18:** Notable stock volatility.
*   **2025-07-19:** Market experts highlighting risks and opportunities.

**Analysis:**

Recent news points to ongoing discussions, volatility, and considerations of both risks and opportunities.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출       |
| :---------- | :----- | :--------- |
| 2025-05-02  | 2.01  | 15.53 B$   |
| 2024-11-06  | 1.25  | 16.66 B$   |
| 2024-08-05  | 2.15  | 16.11 B$   |
| 2024-05-03  | 1.88  | 15.78 B$   |
| 2025-05-02  | 1.88  | 15.78 B$   |

**Analysis:**

EPS and revenue have fluctuated. Recent EPS figures show variability.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| :------------- | :-------- | :-------------- |
| 2025-03-31  | $15.53B | 77.98%          |
| 2024-12-31  | $15.62B | 75.50%          |
| 2024-09-30  | $16.66B | 75.51%          |
| 2024-06-30  | $16.11B | 76.76%          |
| 2024-03-31  | $15.78B | 77.56%          |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
| :------------- | :-------- | :------ |
| 2025-03-31  | $48.34B | 10.51% |
| 2024-12-31  | $46.31B | 8.08%  |
| 2024-09-30  | $44.50B | 7.09%  |
| 2024-06-30  | $43.58B | 12.52% |
| 2024-03-31  | $40.36B | 11.80% |

**Analysis:**

*   Revenue has shown some variability.
*   Profit margins are consistently high.
*   Equity has been increasing.
*   ROE has fluctuated.

### 7. Overall Summary

Based on the provided data, Merck & Co Inc (MRK) exhibits the following key characteristics:

*   **Significant Underperformance:** MRK has severely underperformed the S&P 500, with a large negative divergence.
*   **Volatile Performance:** CAGR and EPS values fluctuate, indicating inconsistencies.
*   **Recent Downtrend:** Price is below short-term moving averages, and the relative divergence is declining.
*   **Hybrid Signal Indication:** Suggests selling.
*   **Negative Outlook:** The exceptionally negative expected return is a significant cause for concern, indicating a pessimistic view of future performance relative to the S&P 500.
*   **Relatively High Profitability:** Revenue and profit margins remain positive.

**Recommendation:**

Given the significant underperformance, negative outlook, and the sell signal indicated, a cautious approach is warranted.  Investors should carefully monitor upcoming earnings, news, and analyst reports. Consider reducing exposure or re-evaluating the investment thesis if the negative trends continue.
